SCHEMBL24019679

SCHEMBL24019679

CC(C)NC(=O)c1cc2c(OC(F)F)cccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
RCE1 Q9Y256 1/20 0.59
HDAC3 O15379 2/20 0.52
HDAC1 Q13547 2/20 0.52
FLT3 P36888 2/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
ALOX15 P16050 1/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
ALB P02768 1/20 0.43
IL2 P60568 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26177804 0.92 KMT2A (0.59) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL23836099 0.85 KMT2A (0.77) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL22235474 0.84 FLT3 (0.52) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL24740808 0.84 KMT2A (0.58) KMT2AMEN1RCE1RAB9ANPC1
SCHEMBL29943636 0.82 SRD5A2 (0.59) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL3616170 0.82 SRD5A2 (0.59) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL24019971 0.82 KMT2A (0.59) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL29063423 0.81 HDAC3 (0.50) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL29943469 0.81 FLT3 (0.48) KMT2AMEN1RCE1HDAC3HDAC1
SCHEMBL24019693 0.81 ALB (0.60) KMT2AMEN1RCE1FLT3ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-22 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-05-26 US disclosed
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-04-26 US disclosed
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2021-11-18 US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312704-B2 Inhibitors of cysteine proteases and methods of use thereof CTSV, CTRL, CTSL KMT2A 3478/4885MEN1 4363/4885RCE1 41/4885
US-20220162194-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL KMT2A 3478/4885MEN1 4363/4885RCE1 41/4885
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL KMT2A 3478/4885MEN1 4363/4885RCE1 41/4885
US-20210355111-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL KMT2A 3130/4885MEN1 4164/4885RCE1 74/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL KMT2A 3130/4885MEN1 4164/4885RCE1 74/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL KMT2A 3130/4885MEN1 4164/4885RCE1 74/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV KMT2A 3383/4885MEN1 4306/4885RCE1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.